Clinical Study

Novartis Ianalumab Injections For Lupus Nephritis

Posted Date: Aug 2, 2023

  • Investigator: Manish Anand
  • Specialties: Kidney Disease, Nephrology
  • Type of Study: Drug

Brief Summary: This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN as determined by recent biopsy.


Older Than 18, Confirmed Diagnois Of Sle And Renal Biospy Within 6 Months Showing Class Ii, Iv (With Or Without V) Or Class V Alone. Lab Values: Egfr >=25, Upcr >=1.0 G/G From 24 Hour Urine Sample. Exclusions For Severe Renal Impairment, Transplant, Low Hemoglobin, Platelets Or Anc, Intolerance To Mpa Or Corticosteroids


Lupus Nephritis, Proteinuria, Kidney

For More Information:

Manish Anand

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.